Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial

By In The News
July 12, 2019 in The Headlines

Recommended Posts

In The News

Posted July 12, 2019

- Share

Posted July 12, 2019

STOCKHOLM, July 12, 2019 /PRNewswire/ -- Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its first-in-human, clinical phase I, trial with drug candidate T20K, in development for the treatment...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219854
2. Jaydee
  16745
3. Kip Powick
  12210
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.6k

Sign In

Cyxone Announce Dosing of First Volunteer in T20K's First-in-human Trial

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support